HC Wainwright Has Lowered Expectations for Corcept Therapeutics (NASDAQ:CORT) Stock Price

Corcept Therapeutics (NASDAQ:CORT) had its target price cut by investment analysts at HC Wainwright from $67.00 to $60.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price target suggests a potential upside of 48.37% from the stock’s previous close.

Other equities analysts have also issued reports about the company. Canaccord Genuity Group lifted their price objective on Corcept Therapeutics from $99.00 to $100.00 and gave the company a “buy” rating in a research note on Friday, January 23rd. UBS Group initiated coverage on shares of Corcept Therapeutics in a research note on Tuesday, December 16th. They set a “neutral” rating and a $95.00 price objective for the company. Wolfe Research lowered shares of Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $30.00 target price on the stock. in a report on Wednesday, December 31st. Truist Financial set a $50.00 price target on Corcept Therapeutics in a report on Wednesday, December 31st. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Corcept Therapeutics in a research report on Monday, December 29th. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $76.00.

Corcept Therapeutics Trading Up 19.6%

Shares of CORT traded up $6.62 during mid-day trading on Wednesday, hitting $40.44. The company had a trading volume of 9,014,789 shares, compared to its average volume of 2,147,597. Corcept Therapeutics has a 1-year low of $28.66 and a 1-year high of $117.33. The company has a quick ratio of 2.85, a current ratio of 2.92 and a debt-to-equity ratio of 0.01. The business’s 50-day simple moving average is $37.34 and its 200-day simple moving average is $61.30. The stock has a market cap of $4.30 billion, a PE ratio of 49.45 and a beta of 0.29.

Corcept Therapeutics (NASDAQ:CORT) last announced its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.13). The company had revenue of $202.13 million for the quarter, compared to analysts’ expectations of $254.94 million. Corcept Therapeutics had a net margin of 12.96% and a return on equity of 15.19%. The firm’s quarterly revenue was up 11.1% on a year-over-year basis. During the same period in the prior year, the firm earned $0.26 earnings per share. Sell-side analysts forecast that Corcept Therapeutics will post 1.36 earnings per share for the current year.

Insider Buying and Selling at Corcept Therapeutics

In other news, Director G Leonard Baker, Jr. acquired 100,000 shares of the firm’s stock in a transaction on Tuesday, March 17th. The stock was bought at an average cost of $33.14 per share, with a total value of $3,314,000.00. Following the transaction, the director directly owned 1,146,631 shares in the company, valued at approximately $37,999,351.34. This represents a 9.55% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider William Guyer sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $40.87, for a total value of $817,400.00. Following the sale, the insider owned 1,235 shares of the company’s stock, valued at $50,474.45. This represents a 94.18% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 60,000 shares of company stock valued at $2,241,035 over the last 90 days. Insiders own 20.50% of the company’s stock.

Institutional Investors Weigh In On Corcept Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Rockefeller Capital Management L.P. increased its holdings in Corcept Therapeutics by 438.3% during the 4th quarter. Rockefeller Capital Management L.P. now owns 65,797 shares of the biotechnology company’s stock worth $2,290,000 after purchasing an additional 53,574 shares during the last quarter. Corient Private Wealth LLC grew its position in shares of Corcept Therapeutics by 9.3% during the fourth quarter. Corient Private Wealth LLC now owns 7,035 shares of the biotechnology company’s stock worth $245,000 after buying an additional 600 shares in the last quarter. SHP Wealth Management bought a new stake in shares of Corcept Therapeutics in the fourth quarter worth $72,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of Corcept Therapeutics in the fourth quarter worth $8,757,000. Finally, Virtu Financial LLC acquired a new stake in Corcept Therapeutics in the fourth quarter valued at $456,000. 93.61% of the stock is currently owned by hedge funds and other institutional investors.

Key Corcept Therapeutics News

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: FDA approval for relacorilant (Lifyorli) + nab‑paclitaxel opens a new commercial indication (platinum‑resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer). This is the clear immediate catalyst for buying interest — approval arrived ahead of prior timelines and creates a concrete revenue opportunity for Corcept’s lead drug. FDA Approves Corcept’s Selective Glucocorticoid Receptor Antagonist Lifyorli™ (relacorilant) Plus Nab‑Paclitaxel for Treatment of Patients with Platinum‑Resistant Ovarian Cancer
• Positive Sentiment: Analyst support: H.C. Wainwright reiterated a Buy and set a $60 target, signaling sell‑side backing for upside based on the approval and longer‑term sales potential. Analyst commentary likely reinforced investor demand. Corcept Therapeutics: Early Lifyorli Approval and Robust Long‑Term Sales Outlook Underpin Buy Rating and $60 Target
• Positive Sentiment: Insider buying and renewed focus on relacorilant’s regulatory path have supported momentum — a director’s disclosed open‑market purchase and renewed regulatory catalysts helped convince traders that management/patient insiders see value ahead. That positioning amplified the rally. Corcept Therapeutics surges as investors focus on a sizable insider buy and relacorilant’s next regulatory catalyst
• Neutral Sentiment: Trading mechanics: the stock experienced a Regulatory LULD pause (trading halt) during the intraday move — a routine market safeguard during large price swings that can intensify short‑term volatility.
• Neutral Sentiment: Widespread media coverage amplified intraday momentum as outlets reported the approval and the rapid price reaction; high volume and short‑covering likely intensified the move. What’s Behind The Jump In Corcept Therapeutics Stock?
• Negative Sentiment: Litigation risk: multiple law firms have filed/are soliciting plaintiffs in securities class actions tied to past regulatory issues and alleged disclosure problems (lead‑plaintiff deadlines in April). Ongoing litigation can create legal expenses, distraction, and investor uncertainty. Kaplan Fox Continues to Alert Investors of a Securities Class Action Against Corcept Therapeutics, Inc. (NASDAQ: CORT) – Deadline on April 21, 2026
• Negative Sentiment: Insider selling: a disclosed sale by William Guyer (reported March 20) reduced his holdings materially; such sales can be read negatively by some investors even when not unusual or pre‑planned. Insider trade details for William Guyer

About Corcept Therapeutics

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.